Pfizer earns long-awaited full FDA nod for Covid-19 vaccine, a hopeful aid in US campaign
The FDA on Monday announced its full approval for Pfizer and BioNTech’s mRNA-based Covid-19 vaccine for individuals 16 and older, potentially offering a breakthrough on the PR front for the US vaccination campaign.
The vaccine, which previously held an emergency use authorization from the agency, will now market as Comirnaty — a moniker the companies had previously announced, changing from the placeholder “Pfizer-BioNTech Covid-19 Vaccine” name. Children between the ages of 12 and 16 will still have access to the vaccine under the EUA and trials in children younger than 12 are still ongoing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.